|
[1]World Health Organization(WHO).Global battle against cancer won't be won with treatment alone-effective prevention measures urgently needed to prevent cancer crisis[J].Cent Eur J Public Health,2014,22(1):23,28.
|
|
[2]LLOVET JM,BURROUGHS A,BRUIX J.Hepatocellular carcinoma[J].Lancet,2003,362(9399):1907-1917.
|
|
[3]CABRERA R,NELSON DR.Review article:the management of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2010,31(4):461-476.
|
|
[4]SCHLACHTERMAN A,CRAFT WW Jr,HILGENFELDT E,et al.Current and future treatments for hepatocellular carcinoma[J].World J Gastroenterol,2015,21(28):8478-8491.
|
|
[5]HATANAKA Y,YAMASHITA Y,TAKAHASHI M,et al.Unresectable hepatocellular carcinoma:analysis of prognostic factors in transcatheter management[J].Radiology,1995,195(3):747-752.
|
|
[6]MATSUI O.A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma[J].N Engl J Med,1995,332(19):1256-1261.
|
|
[7]LLOVET JM,REAL MI,MONTANA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.
|
|
[8]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.
|
|
[9]MURATA S,MINE T,SUGIHARA F,et al.Interventional treatment for unresectable hepatocellular carcinoma[J].World J Gastroenterol,2014,20(37):13453-13465.
|
|
[10]KANAZAWA S.Current status of interventional oncology[J].Int J Clin Oncol,2012,17(4):299-300.
|
|
[11]KINOSHITA A,ONODA H,FUSHIYA N,et al.Staging systems for hepatocellular carcinoma:current status and future perspectives[J].World J Hepatol,2015,7(3):406-424.
|
|
[12]LLOVET JM,DI BISCEGLIE AM,BRUIX J,et al.Design and endpoints of clinical trials in hepatocellular carcinoma[J].J Natl Cancer Inst,2008,100(10):698-711.
|
|
[13]FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
|
|
[14]PISCAGLIA F,BOLONDI L.The intermediate hepatocellular carcinoma stage:should treatment be expanded?[J].Dig Liver Dis,2010,42(Suppl 3):s258-s263.
|
|
[15]RAOUL JL,SANGRO B,FORNER A,et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev,2011,37(3):212-220.
|
|
[16]DUFOUR JF,BARGELLINI I,DE MARIA N,et al.Intermediate hepatocellular carcinoma:current treatments and future perspectives[J].Ann Oncol,2013,24(Suppl 2):ii24-ii29.
|
|
[17]LAMMER J,MALAGARI K,VOGL T,et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol,2010,33(1):41-52.
|
|
[18]SIEGHART W,HUCKE F,PINTER M,et al.The ART of decision making:retreatment with transarterial chemoembolization in patients withhepatocellular carcinoma[J].Hepatology,2013,57(6):2261-2273.
|
|
[19]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.
|
|
[20]YAU T,TANG VY,YAO TJ,et al.Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J].Gastroenterology,2014,146(7):1691-1700.
|
|
[21]KUDO M.Real practice of hepatocellular carcinoma in Japan:conclusions of the Japan Society of Hepatology 2009 Kobe Congress[J].Oncology,2010,78(Suppl 1):180-188.
|
|
[22]WILLATT JM,FRANCIS IR,NOVELLI PM,et al.Interventional therapies for hepatocellular carcinoma[J].Cancer Imaging,2012,12:79-88.
|
|
[23]LU Z,WEN F,GUO Q,et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma:a meta-analysis of randomized-controlled trials[J].Eur J Gastroenterol Hepatol,2013,25(2):187-194.
|
|
[24]NI JY,LIU SS,XU LF,et al.Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma:a meta-analysis[J].J Cancer Res Clin Oncol,2013,139(4):653-659.
|
|
[25]FU Y,ZHAO X,YUN Q,et al.Transarterial chemoembolization(TACE)plus percutaneous ethanol injection(PEI)for the treatment of unresectable hepatocellular carcinoma:a meta-analysis of randomized controlled trials[J].Int J Clin Exp Med,2015,8(7):10388-10400.
|
|
[26]KIM J,CHUNG DJ,JUNG SE,et al.Therapeutic effect of highintensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma<5 cm:comparison with transarterial chemoembolisation monotherapy-preliminary observations[J].Br J Radiol,2012,85(1018):e940-e946.
|
|
[27]MORIMOTO M,NUMATA K,KONDOU M,et al.Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma:a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J].Cancer,2010,116(23):5452-5460.
|
|
[28]PENG S,YANG QX,ZHANG T,et al.Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2014,15(13):5155-5160.
|
|
[29]HUO YR,ESLICK GD.Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:a systematic review and meta-analysis[J].JAMA Oncol,2015,1(6):756-765.
|
|
[30]JEONG Y,YOON SM,HAN S,et al.Propensity score matching analysis of changes in alpha-fetoprotein levels after combined radiotherapy and transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus[J].PLoS One,2015,10(8):e0135298.
|
|
[31]YAO FY,KERLAN RK JR,HIROSE R,et al.Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation:an intention-to-treat analysis[J].Hepatology,2008,48(3):819-827.
|
|
[32]CUCCHETTI A,CESCON M,BIGONZI E,et al.Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy[J].Liver Transpl,2011,17(11):1344-1354.
|
|
[33]BELGHITI J,CARR BI,GREIG PD,et al.Treatment before liver transplantation for HCC[J].Ann Surg Oncol,2008,15(4):993-1000.
|
|
[34]SCHWARTZ M,ROAYAIE S,UVA P.Treatment of HCC in patients awaiting liver transplantation[J].Am J Transplant,2007,7(8):1875-1881.
|
|
[35]LLOVET JM,MAS X,APONTE JJ,et al.Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J].Gut,2002,50(1):123-128.
|
|
[36]BOUCHARD-FORTIER A,LAPOINTE R,PERREAULT P,et al.Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation:a retrospective study[J].Int J Hepatol,2011,2011:974514.
|
|
[37]RAMPONE B,SCHIAVONE B,MARTINO A,et al.Current management strategy of hepatocellular carcinoma[J].World J Gastroenterol,2009,15(26):3210-3216.
|
|
[38]GIGLIA JL,ANTONIA SJ,BERK LB,et al.Systemic therapy for advanced hepatocellular carcinoma:past,present,and future[J].Cancer Control,2010,17(2):120-129.
|
|
[39]CHEN KW,OU TM,HSU CW,et al.Current systemic treatment of hepatocellular carcinoma:a review of the literature[J].World J Hepatol,2015,7(10):1412-1420.
|
|
[40]PAWLIK TM,REYES DK,COSGROVE D,et al.PhaseⅡtrial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J].J Clin Oncol,2011,29(30):3960-3967.
|
|
[41]PARK JW,KOH YH,KIM HB,et al.PhaseⅡstudy of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma[J].J Hepatol,2012,56(6):1336-1342.
|
|
[42]CHUNG YH,HAN G,YOON JH,et al.Interim analysis of START:study in Asia of the combination of TACE(transcatheter arterial chemoembolization)with sorafenib in patients with hepatocellular carcinoma trial[J].Int J Cancer,2013,132(10):2448-2458.
|
|
[43]LENCIONI R,LLOVET JM,HAN G,et al.Sorafenib or placebo in combination with transarterial chemoembolization(TACE)with doxorubicin-eluting beads(DEBDOX)for intermediate stage hepatocellular carcinoma(HCC):phaseⅡ,randomized,doubleblind SPACE trial[J].J Clin Oncol,2012,30(Suppl 4):154.
|
|
[44]QU XD,CHEN CS,WANG JH,et al.The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J].BMC Cancer,2012,12:263.
|
|
[45]SACHDEVA M,CHAWLA YK,ARORA SK.Immunology of hepatocellular carcinoma[J].World J Hepatol,2015,7(17):2080-2090.
|
|
[46]YANG HI,LU SN,LIAW YF,et al.Hepatitis B e antigen and the risk of hepatocellular carcinoma[J].N Engl J Med,2002,347(3):168-174.
|
|
[47]DAVIS CR.Interventional radiological treatment of hepatocellular carcinoma[J].Cancer Control,2010,17(2):87-99.
|
DownLoad: